Marie C Hogan

List of Publications by Year
in descending order

75 papers	4,463 citations	136950 32 h-index	106344 65 g-index
75 all docs	75 docs citations	75 times ranked	3853 citing authors

#	Article	IF	Citations
1	The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nature Genetics, 2002, 30, 259-269.	21.4	683
2	Imaging Classification of Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2015, 26, 160-172.	6.1	439
3	Mutations in GANAB , Encoding the Glucosidase IIÎ± Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. American Journal of Human Genetics, 2016, 98, 1193-1207.	6.2	345
4	Characterization of PKD Protein-Positive Exosome-Like Vesicles. Journal of the American Society of Nephrology: JASN, 2009, 20, 278-288.	6.1	300
5	Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease. Journal of the American Society of Nephrology: JASN, 2010, 21, 1052-1061.	6.1	288
6	COVID-19 Vaccination and Glomerulonephritis. Kidney International Reports, 2021, 6, 2969-2978.	0.8	135
7	The HALT Polycystic Kidney Disease Trials. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 102-109.	4.5	125
8	Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrology Dialysis Transplantation, 2012, 27, 3532-3539.	0.7	120
9	DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney International Reports, 2018, 3, 56-64.	0.8	109
10	Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2018, 29, 571-578.	6.1	101
11	Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology, 2013, 58, 409-421.	7.3	96
12	Health-Related Quality of Life in Patients With Autosomal DominantÂPolycystic Kidney Disease and CKD Stages 1-4: AÂCross-sectional Study. American Journal of Kidney Diseases, 2014, 63, 214-226.	1.9	93
13	Subfractionation, characterization, and in-depth proteomic analysis of glomerular membrane vesicles in human urine. Kidney International, 2014, 85, 1225-1237.	5.2	92
14	Liver Involvement in Early Autosomal-Dominant Polycystic Kidney Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 155-164.e6.	4.4	90
15	Dietary salt restriction is beneficial to the management of autosomal dominant polycysticÂkidney disease. Kidney International, 2017, 91, 493-500.	5.2	80
16	Young Women With Polycystic Liver Disease Respond Best to Somatostatin Analogues: A Pooled Analysis of Individual Patient Data. Gastroenterology, 2013, 145, 357-365.e2.	1.3	76
17	Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney International, 2012, 81, 577-585.	5.2	74
18	Evaluation and Management of Pain in Autosomal Dominant Polycystic Kidney Disease. Advances in Chronic Kidney Disease, 2010, 17, e1-e16.	1.4	72

#	Article	IF	Citations
19	Association Between Prior Peripherally Inserted Central Catheters and Lack of Functioning Arteriovenous Fistulas: A Case-Control Study in Hemodialysis Patients. American Journal of Kidney Diseases, 2012, 60, 601-608.	1.9	62
20	Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. American Journal of Human Genetics, 2022, 109, 136-156.	6.2	62
21	Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1153-1161.	4.5	60
22	PKHDL1, a homolog of the autosomal recessive polycystic kidney disease gene, encodes a receptor with inducible T lymphocyte expression. Human Molecular Genetics, 2003, 12, 685-698.	2.9	54
23	Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 952-960.	0.7	54
24	The relatively poor correlation between random andÂ24-hour urine protein excretion in patients withÂbiopsy-proven glomerular diseases. Kidney International, 2016, 90, 1080-1089.	5.2	51
25	Evaluating healthâ€related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver International, 2014, 34, 1578-1583.	3.9	50
26	Unusual presentation of multiple myeloma with unilateral visual loss and numb chin syndrome in a young adult. American Journal of Hematology, 2002, 70, 55-59.	4.1	47
27	Cardiac Magnetic Resonance Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2508-2515.	4.5	43
28	Development and Validation of a Diseaseâ€Specific Questionnaire to Assess Patientâ€Reported Symptoms in Polycystic Liver Disease. Hepatology, 2016, 64, 151-160.	7.3	43
29	Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies. Kidney International Reports, 2017, 2, 913-923.	0.8	42
30	Purification of Exosome-Like Vesicles from Urine. Methods in Enzymology, 2013, 524, 225-241.	1.0	41
31	Outcomes and Durability of Hepatic Reduction after Combined Partial Hepatectomy and Cyst Fenestration for Massive Polycystic Liver Disease. Journal of the American College of Surgeons, 2016, 223, 118-126e1.	0.5	38
32	A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2014, 29, iv142-iv153.	0.7	34
33	Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease. Mayo Clinic Proceedings, 2015, 90, 1030-1037.	3.0	32
34	All-trans-retinoic acid-induced myositis: A description of two patients. American Journal of Hematology, 2000, 63, 94-98.	4.1	30
35	Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1267-1278.	4.5	24
36	Two cases of non-O157:H7 Escherichia coli hemolytic uremic syndrome caused by urinary tract infection. American Journal of Kidney Diseases, 2001, 38, e22.1-e22.6.	1.9	22

#	Article	IF	Citations
37	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrologyâ€“Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. American Journal of Kidney Diseases, 2021, 77, 255-263.	1.9	21
38	Identification of Genetic Causes of Focal Segmental Glomerulosclerosis Increases With Proper Patient Selection. Mayo Clinic Proceedings, 2021, 96, 2342-2353.	3.0	20
39	PKHDL1, a homolog of the autosomal recessive polycystic kidney disease gene, encodes a receptor with inducible T lymphocyte expression. Human Molecular Genetics, 2003, 12, 685-98.	2.9	20
40	A case report of sevelamer-associated recto-sigmoid ulcers. BMC Gastroenterology, 2016, 16, 20.	2.0	17
41	Analysis of the polycystin complex (PCC) in human urinary exosomeâ€“like vesicles (ELVs). Scientific Reports, 2020, 10, 1500.	3.3	17
42	Negative Staining for COL4A5 Correlates With Worse Prognosis and More Severe Ultrastructural Alterations in Males With Alport Syndrome. Kidney International Reports, 2017, 2, 44-52.	0.8	16
43	Polycystic Liver Disease: The Benefits of Targeting cAMP. Clinical Gastroenterology and Hepatology, 2016, 14, 1031-1034.	4.4	15
44	The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression. BMC Nephrology, 2017, 18, 169.	1.8	15
45	Strategy and rationale for urine collection protocols employed in the NEPTUNE study. BMC Nephrology, 2015, 16, 190.	1.8	14
46	Epidemiology of autosomal-dominant polycystic liver disease in Olmsted county. JHEP Reports, 2020, 2, 100166.	4.9	14
47	The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. CKJ: Clinical Kidney Journal, 2020, 13, 597-606.	2.9	14
48	Establishing a nephrology genetic clinic. Kidney International, 2021, 100, 254-259.	5.2	14
49	Urinary CD80 Discriminates Among Glomerular Disease Types and Reflects Disease Activity. Kidney International Reports, 2020, 5, 2021-2031.	0.8	13
50	Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials. PLoS ONE, 2021, 16, e0257606.	2.5	12
51	Epstein-Barr virus-associated nephrotic syndrome. CKJ: Clinical Kidney Journal, 2012, 5, 50-52.	2.9	10
52	Crystalglobulin-Induced Nephropathy and Keratopathy. Kidney Medicine, 2019, 1, 71-74.	2.0	10
53	Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease. Surgery, 2020, 168, 25-32.	1.9	10
54	Characteristics of Patients with End-Stage Kidney Disease in ADPKD. Kidney International Reports, 2021, 6, 755-767.	0.8	10

#	Article	IF	Citations
55	Developing a patient-centred tool for pain measurement and evaluation in autosomal dominant polycystic kidney disease. CKJ: Clinical Kidney Journal, 2021, 14, 2338-2348.	2.9	9
56	Evaluating safety of tunneled small bore central venous catheters in chronic kidney disease population: A quality improvement initiative. Hemodialysis International, 2017, 21, 284-293.	0.9	7
57	Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2018, 3, 619-624.	0.8	7
58	Congenital Heart Disease in Adults with Autosomal Dominant Polycystic Kidney Disease. American Journal of Nephrology, 2022, 53, 316-324.	3.1	7
59	Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis. Liver International, 2016, 36, 595-602.	3.9	6
60	Prospective Study of Routine Heparin Avoidance Hemodialysis in a Tertiary Acute Care Inpatient Practice. Kidney International Reports, 2017, 2, 695-704.	0.8	6
61	Pancreatic Cysts and Intraductal Papillary Mucinous Neoplasm in Autosomal Dominant Polycystic Kidney Disease. Pancreas, 2019, 48, 698-705.	1.1	6
62	ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing. American Journal of Kidney Diseases, 2018, 71, 294-296.	1.9	5
63	Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease. Nephrology Dialysis Transplantation, 2021, 36, 1821-1827.	0.7	5
64	A practical guide for the management of acute abdominal pain with fever in patients with autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2022, 37, 1426-1428.	0.7	5
65	Mitochondriopathy Manifesting as Inherited Tubulointerstitial Nephropathy Without Symptomatic Other Organ Involvement. Kidney International Reports, 2021, 6, 2514-2518.	0.8	5
66	Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 149-159.	2.4	4
67	Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review. PLoS ONE, 2021, 16, e0252479.	2.5	4
68	APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. Pediatric Nephrology, 2021, 36, 2747-2757.	1.7	3
69	Establishing a core outcome measure for pain in patients with autosomal dominant polycystic kidney disease: a consensus workshop report. CKJ: Clinical Kidney Journal, 2022, 15, 407-416.	2.9	3
70	Extrarenal Manifestations of Autosomal Dominant Polycystic Kidney Disease: Polycystic Liver Disease. , 2018, , 171-195.		3
71	Detection of High Molecular Weight Light Chain Oligomers in Urinary Exosomes of Patients with AL Amyloidosis.. Blood, 2009, 114, 4886-4886.	1.4	3
72	Allâ€transâ€retinoic acidâ€induced myositis: A description of two patients. American Journal of Hematology, 2000, 63, 94-98.	4.1	2

#	Article	IF	Citations
73	What the similarities of specific polycystic liver and kidney diseases can teach us about both. Nephrology News & Issues, 2008, 22, 29-31.	0.1	2
74	Closeout of the HALT-PKD trials. Contemporary Clinical Trials, 2015, 44, 48-55.	1.8	1
75	SP003GENETIC TESTING IN SUSPECTED HEREDITARY PROTEINURIC KIDNEY DISEASES. Nephrology Dialysis Transplantation, 2018, 33, i346-i347.	0.7	1